Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials - PubMed (original) (raw)
Meta-Analysis
doi: 10.1111/dom.12085. Epub 2013 Mar 20.
Affiliations
- PMID: 23433305
- DOI: 10.1111/dom.12085
Meta-Analysis
Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials
B Wang et al. Diabetes Obes Metab. 2013 Aug.
Abstract
Aims: Aside from lowering blood glucose, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) attract much attention because of their cardioprotective effects. The aim of this study was to assess the blood pressure-lowering effects of the GLP-1 RAs exenatide and liraglutide compared with other common drugs used to treat type 2 diabetes (T2DM) based on randomized controlled trials (RCTs) including data describing complete blood pressure (BP) changes from baseline.
Methods: We searched the major databases for published or unpublished RCTs that had been performed in patients with T2DM and compared the effects of exenatide and liraglutide to those of other common drugs used to treat T2DM. The RCTs that included data describing BP changes between the baseline and the end of the study were selected for further analysis.
Results: A total of 16 RCTs that enrolled 3443 patients in the GLP-1 RA treatment group and 2417 subjects in the control group were included in this meta-analysis. The GLP-1 RA exenatide reduced systolic blood pressure (SBP) when compared with both placebo and insulin glargine, with mean differences of -5.24 and -3.46 mmHg, respectively, and with 95% confidence intervals (CI) of -6.88 to -3.59, p < 0.00001 and -3.63 to -3.29, p < 0.00001, respectively. Meanwhile, in the exenatide-treated group, diastolic blood pressure (DBP) was reduced by -5.91 mmHg, with a 95% CI of -7.53 to -4.28, p < 0.00001 compared with the placebo group, and -0.99 mmHg with a 95% CI of -1.12 to -0.87, p < 0.00001 compared with the sitagliptin group. SBP changes in this meta-analysis were assessed in the groups treated with 1.2 or 1.8 mg liraglutide per day. In the 1.2 mg-treated group, liraglutide treatment reduced SBP compared with placebo and glimepiride treatment, with mean differences of -5.60 and -2.38 mmHg, and 95% CIs of -5.84 to -5.36, p < 0.00001 and -4.75 to -0.01, p = 0.05, respectively. In the 1.8-mg-treated group, liraglutide also reduced SBP compared with placebo and glimepiride treatment with mean differences of -4.49 and -2.62 mmHg, and a 95% CI of -4.73 to -4.26, p < 0.00001, and -2.91 to -2.33, p < 0.00001, respectively.
Conclusion: Treatment with the GLP-1 RAs exenatide and liraglutide reduced SBP and DBP by 1 to 5 mmHg compared with some other anti-diabetic drugs including insulin, glimepiride and placebo for patients with T2DM. GLP-1 RAs may offer an alternative therapy for these patients and will help provide extra cardiovascular benefits.
Keywords: GLP-1; hypertension; meta-analysis; randomized trials.
© 2013 Blackwell Publishing Ltd.
Similar articles
- Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B, Bonnard C, Renard E. Vergès B, et al. Diabetes Metab. 2011 Dec;37(6):477-88. doi: 10.1016/j.diabet.2011.07.001. Epub 2011 Aug 25. Diabetes Metab. 2011. PMID: 21871831 Review. - Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, Zhang Y, Quan X, Ji L, Zhan S. Sun F, et al. Diabetes Res Clin Pract. 2015 Oct;110(1):26-37. doi: 10.1016/j.diabres.2015.07.015. Epub 2015 Aug 13. Diabetes Res Clin Pract. 2015. PMID: 26358202 Review. - Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
Jendle J, Torffvit O, Ridderstråle M, Ericsson Å, Nilsen B, Bøgelund M. Jendle J, et al. J Med Econ. 2012;15 Suppl 2:1-5. doi: 10.3111/13696998.2012.703633. Epub 2012 Aug 1. J Med Econ. 2012. PMID: 22853443 - Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF, Mannucci E, Ahrén B. Deacon CF, et al. Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24. Diabetes Obes Metab. 2012. PMID: 22471248 Review. - GLP-1 receptor agonists: effects on cardiovascular risk reduction.
Lorber D. Lorber D. Cardiovasc Ther. 2013 Aug;31(4):238-49. doi: 10.1111/1755-5922.12000. Cardiovasc Ther. 2013. PMID: 23865382 Review.
Cited by
- Nasal turbinate lymphatic obstruction: a proposed new paradigm in the etiology of essential hypertension.
Phillips WT, Schwartz JG. Phillips WT, et al. Front Med (Lausanne). 2024 Aug 16;11:1380632. doi: 10.3389/fmed.2024.1380632. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39219790 Free PMC article. - Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group.
Janez A, Muzurovic E, Bogdanski P, Czupryniak L, Fabryova L, Fras Z, Guja C, Haluzik M, Kempler P, Lalic N, Mullerova D, Stoian AP, Papanas N, Rahelic D, Silva-Nunes J, Tankova T, Yumuk V, Rizzo M. Janez A, et al. Diabetes Ther. 2024 Sep;15(9):1865-1892. doi: 10.1007/s13300-024-01615-5. Epub 2024 Jul 11. Diabetes Ther. 2024. PMID: 38990471 Free PMC article. Review. - Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population.
Natale F, Luisi E, Franzese R, Mollo N, Solimene A, Caso VM, Corvino A, Golino P, Cimmino G. Natale F, et al. J Cardiovasc Dev Dis. 2024 May 7;11(5):145. doi: 10.3390/jcdd11050145. J Cardiovasc Dev Dis. 2024. PMID: 38786967 Free PMC article. Review. - Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies.
Szczesnowicz A, Szeliga A, Niwczyk O, Bala G, Meczekalski B. Szczesnowicz A, et al. J Clin Med. 2023 Sep 12;12(18):5915. doi: 10.3390/jcm12185915. J Clin Med. 2023. PMID: 37762856 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical